Search Videos and More
Kidney Cancer Updates - GU Oncology Cancer Highlights: ESMO 2024
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ESMO 2024.Bladder Cancer Updates - GU Oncology Cancer Highlights: ESMO 2024
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from ESMO 2024.Prostate Cancer Updates - GU Oncology Cancer Highlights: ESMO 2024
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ESMO 2024.Dana-Farber Research News 11.01.2024
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from October 1 through October 15.Innovative Endometrial Cancer Research Offers Fresh Promise for Patients
For the past decade, new cases of endometrial (uterine) cancer have been on the rise in the United States. The past few years, however, have brought a more promising rise: A new generation of drugs and drug combinations that are improving the outlook for patients with the disease.Dana-Farber Research News 10.15.2024
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from September 16 through September 30.Rapid Blood Cancer Diagnostic Could Speed Decisions and Save Lives
Researchers at Dana-Farber Cancer Institute have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions.Study Finds Unexpected Role for Odd-Man-Out Member of CDK Protein Family
In the family of cyclin-dependent kinase (CDK) proteins, CDK5 always seemed to be a misfit. Despite being structurally similar to other CDKs, and despite the “cyclin” in its name, it did not participate in the family business of ushering cells through the cycle of growth and division.Dana-Farber/Boston Children's Ranked Among the Best Pediatric Cancer Programs in the Nation for 18th Year in a Row
U.S. News & World Report has again recognized Dana-Farber/Boston Children's Cancer and Blood Disorders Center as the #2 pediatric cancer program in the nation in its 2024-25 Best Children's Hospitals report.Dana-Farber Research News 10.01.2024
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from September 1 through September 15.Dana-Farber Cancer Institute Raises More Than $2 Billion in Record-Breaking Fundraising Campaign to Defy Cancer
Dana-Farber Cancer Institute today announced the completion of one of the largest fundraising campaigns focused entirely on cancer, raising a record $2.5 billion.Patient, Testing Positive for Cancer on Early-Detection Test, Finds Guidance at Dana-Farber Clinic
Scott Menta describes himself as someone who “likes to stay on top of my health.” So, when he read about a new test that screens for cancer based on tumor cell DNA within the blood, he sprang for the cost of two tests — one for him and one for his wife.